Agitation in Demented Patients in the United States

1997 ◽  
Vol 8 (S3) ◽  
pp. 487-490 ◽  
Author(s):  
Jacobo E. Mintzer ◽  
Paul Nietert ◽  
Kerri Costa ◽  
L. Randolph Waid

Alzheimer's disease and other dementing disorders have been reported in most ethnic groups living in the United States. Although the presence of these disorders in different U.S. ethnic groups is well documented, the characteristics of dementing disorders, such as the presence of behavioral disturbances, in these groups remains unexplored.

2021 ◽  
pp. 1-13
Author(s):  
Maria Pisu ◽  
Roy C. Martin ◽  
Liang Shan ◽  
Giovanna Pilonieta ◽  
Richard E. Kennedy ◽  
...  

Background: Use of specialists and recommended drugs has beneficial effects for older adults living with Alzheimer’s disease and related dementia (ADRD). Gaps in care may exist for minorities, e.g., Blacks, and especially in the United States (U.S.) Deep South (DS), a poor U.S. region with rising ADRD cases and minority overrepresentation. Currently, we have little understanding of ADRD care utilization in diverse populations in this region and elsewhere in the U.S. (non-DS), and the factors that adversely impact it. Objective: To examine utilization of specialists and ADRD drugs (outcomes) in racial/ethnic groups of older adults with ADRD and the personal or context-level factors affecting these outcomes in DS and non-DS. Methods: We obtained outcomes and personal-level covariates from claims for 127,512 Medicare beneficiaries with ADRD in 2013–2015, and combined county-level data in exploratory factor analysis to define context-level covariates. Adjusted analyses tested significant association of outcomes with Black/White race and other factors in DS and non-DS. Results: Across racial/ethnic groups, 33%–43% in DS and 43%–50% in non-DS used specialists; 47%–55% in DS and 41%–48% in non-DS used ADRD drugs. In adjusted analyses, differences between Blacks and Whites were not significant. Vascular dementia, comorbidities, poverty, and context-level factor “Availability of Medical Resources” were associated with specialist use; Alzheimer’s disease and senile dementia, comorbidities, and specialist use were associated with drug use. In non-DS only, other individual, context-level covariates were associated with the outcomes. Conclusion: We did not observe significant gaps in ADRD care in DS and non-DS; however, research should further examine determinants of low specialist and drug use in these regions.


1997 ◽  
Vol 8 (S3) ◽  
pp. 217-218 ◽  
Author(s):  
Barry D. Lebowitz

As the population ages in the United States and other countries, we will be confronted with an increasing number of patients with neurodegenerative disorders, such as Alzheimer's disease and Parkinson's disease. The progressive cognitive impairment that characterizes Alzheimer's disease leaves patients increasingly unable to care for themselves. Patients with Alzheimer's disease also are prone to dementia-related behavioral disturbances, which can range from annoying (such as repetitive questioning) to disturbing (such as vocal outbursts) to dangerous (such as hitting and pushing).


2019 ◽  
Author(s):  
Clemens Kruse ◽  
Britney Larson ◽  
Reagan Wilkinson ◽  
Roger Samson ◽  
Taylor Castillo

BACKGROUND Incidence of AD continues to increase, making it the most common cause of dementia and the sixth-leading cause of death in the United States. 2018 numbers are expected to double by 2030. OBJECTIVE We examined the benefits of utilizing technology to identify and detect Alzheimer’s disease in the diagnostic process. METHODS We searched PubMed and CINAHL using key terms and filters to identify 30 articles for review. We analyzed these articles and reported them in accordance with the PRISMA guidelines. RESULTS We identified 11 technologies used in the detection of Alzheimer’s disease: 66% of which used some form of MIR. Functional, structural, and 7T magnetic resonance imaging were all used with structural being the most prevalent. CONCLUSIONS MRI is the best form of current technology being used in the detection of Alzheimer’s disease. MRI is a noninvasive approach that provides highly accurate results in the diagnostic process of Alzheimer’s disease.


1996 ◽  
Vol 17 (4) ◽  
pp. S95
Author(s):  
L. Hebert ◽  
P. Scherr ◽  
L. Beckett ◽  
D. Evans

2014 ◽  
Vol 10 (2) ◽  
pp. e40-e46 ◽  
Author(s):  
Jennifer Weuve ◽  
Liesi E. Hebert ◽  
Paul A. Scherr ◽  
Denis A. Evans

Author(s):  
Angela M Lunde ◽  
Ronald C Petersen ◽  
John A Lucas

In the United States, the National Alzheimer’s Project Act was signed into law in January 2011, and the first National Plan appeared just over 12 months later, with five goals: to prevent and effectively treat Alzheimer’s disease by 2025, to enhance care quality and efficiency, to expand support for people with Alzheimer’s disease and their families, to enhance public awareness and engagement, and to improve data to track progress. The National Plan has seen a rise in research funding (currently standing at US$1.4 billion). Individual states, at the same time, began discussions about initiatives aimed at addressing personal, societal, and financial implications of Alzheimer’s disease. An example is from Minnesota where counselling and support for caregivers are provided, with an estimated saving for the state of Minnesota of US$970 million by 2025. In addition, a number of treatment trials are under way, looking at the effect of monoclonal antibodies on Alzheimer’s disease and a series of genetic studies.


2019 ◽  
Vol 22 ◽  
pp. S280
Author(s):  
K. Saxena ◽  
J. Sullivan ◽  
R. Khandker ◽  
A.S. Ward ◽  
C. Black ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document